ValorQ4, 24Q4, 25TTMGastos comerciales, generales y administrativos———Investigación y desarrollo———Beneficio operativo-139.87 M-70.34 M-397.68 MTotal de ingresos no operativos———Gastos por intereses, netos de intereses capitalizados———Ingresos no operativos, una vez deducidos los gastos por intereses———Ingresos/gastos extraordinarios———Beneficio antes de impuestos121.15 M490.26 M1.55 BParticipación en los beneficios———Impuestos11.5 M144.74 M152.24 MParticipación minoritaria———Otros ingresos/gastos después de impuestos———Beneficio neto antes de actividades interrumpidas109.65 M345.52 M1.4 BOperaciones suspendidas———Beneficio neto109.65 M345.52 M1.4 BAjuste por dilución———Dividendos de las acciones preferentes———Beneficio neto diluido atribuible a los accionistas109.65 M345.52 M1.4 BBeneficio básico por acción———Beneficio por acción diluido0.491.586.36Número medio de acciones ordinarias222.62 M217.22 M876.26 MAcciones diluidas224.72 M218.88 M884.84 MEBITDA———EBIT———Costo de los ingresos———Otros costes de producción———Amortización y depreciación (flujo de caja)84.87 M70.34 M342.68 M
Qiagen N.V
QIAGEN N.V. is a German-founded multinational provider of sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. The company operates in more than 35 offices in over 25 countries. QIAGEN N.V., the global corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. The main operative headquarters are located in Hilden, Germany. European, American, Chinese, and Asian-Pacific regional headquarters are located respectively in Hilden, Germany; Germantown, Maryland, United States; Shanghai, China; and Singapore. QIAGEN's shares are listed at the NYSE and at the Frankfurt Stock Exchange in the Prime Standard. Thierry Bernard is the company's Chief Executive Officer.